Clinical Trials Engine Lentiviral engineered T cells for HIV
Clinical Trials Engine Lentiviral engineered T cells for HIV
批准号:
7576856
负责人:
CARL H. JUNE
金额:
$79.87万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2009-02-28
关键词:
AIDS/HIV problemAddendumAdoptive ImmunotherapyAntiviral AgentsAntiviral TherapyAntiviral resistanceAutologousBiopsyBloodCD34 geneCD4 Positive T LymphocytesCell Culture SystemCell SurvivalCellsClinicClinicalClinical ProtocolsClinical ResearchClinical TrialsCollaborationsCultured CellsCyclic GMPDailyDataDoseEngineeringEngraftmentEvaluationGene TransferGene-ModifiedGenerationsGoalsHIVHIV InfectionsHIV therapyHIV-1Highly Active Antiretroviral TherapyHuman EngineeringImmunotherapyInfectionInfusion proceduresInsertional MutagenesisInterruptionLabelLaboratoriesLeadLentivirus VectorLymphoidLymphoid TissueMeasuresPatientsPennsylvaniaPersonal SatisfactionPharmaceutical PreparationsPhasePilot ProjectsPositioning AttributeRangeRelative (related person)Research Ethics CommitteesResearch SubjectsResistanceRiskSafetySamplingStagingStem cellsStructureSubfamily lentivirinaeSystemT-LymphocyteTechnologyTestingTherapeuticTherapeutic EffectTissuesTransgenesUniversitiesViralViral Load resultbasecellular transductionclinically relevantexperiencegene therapyimmune functionimmuno-gene therapyimmunogenicityimprovedin vivointerestisopentenyl methylenediphosphonatenovelperipheral bloodpilot trialtraffickingvector
中文摘要
过继转移的T淋巴细胞对HIV感染有治疗前景的原理是很好的
确立了习我们的长期目标是建立慢病毒工程T细胞输注的安全性,
测试第二代转基因的安全性和提高抗病毒效果。我们的长远目标是
提醒艾滋病病毒感染者每日服用抗病毒药物的必要性。在最近完成的
在第一阶段的初步研究中,我们已经证明了单次输注慢病毒的安全性和可行性。
当给予患有晚期HAART的HIV感染受试者时,
抵抗艾滋病毒感染。到目前为止,还没有插入突变的证据,有一个受试者
病毒载量减少了基因修饰的T细胞的植入和持久性是
这是令人满意的,并表明VSV-G假型HIV为基础的慢病毒载体系统是非免疫原性的。
基于我们以前对共刺激的CD 4 T细胞的研究,我们现在假设多个
输注表达VRX 496反义env转基因的慢病毒工程化自体CD 4 T细胞
将导致持续和更高水平的植入。我们进一步假设,转基因将赋予
抗病毒作用。两个临床试验,提出了测试这些假设。首先,我们将进行多次给药
在HAART抑制病毒复制的患者中进行的I/II期研究。结构化处理
将进行中断以评估抗病毒疗效,并将使用淋巴活检来确定
工程化的CD 4 T细胞的组织运输。在试验#2中,我们将测试项目中开发的慢病毒载体
3,其表达更有效的抗病毒产物。我们将比较T细胞的相对存活率
将用第二代载体转导的细胞转化至用在
试验#1。总之,这些试验将代表慢病毒工程化T细胞用于
它们作为治疗HIV-1感染的有效抗病毒疗法的潜力。该项目相互作用
项目2和3,该项目依赖于核心A和B进行cGMP慢病毒载体生产,
用于临床级T细胞扩增和转导技术
英文摘要
The principle that adoptively transferred T lymphocytes have therapeutic promise for HIV infection is well
established. Our long range goals are to establish the safety of infusions of lentiviral engineered T cells, and
to test second generation transgenes for safety and improved antiviral efficacy. Our long range objective is
to obviate the need to take daily antiviral medications in patients with HIV infection. In a recently completed
phase I pilot study, we have demonstrated the safety and feasibility of a single infusion of lentiviral
engineered autologous CD4 T cells when administered to HIV infected subjects with late-stage, HAART
resistant HIV infection. To date, there is no evidence of insertional mutagenesis, and one subject has
experienced a reduction in viral load. The engraftment and persistence of the gene-modified T cells is
satisfactory and suggests that the VSV-G pseudotyped HIV-based lentiviral vector system is nonimmunogenic.
Based on our previous studies of costimulated CD4 T cells, we now hypothesize that multiple
infusions of lentiviral engineered autologous CD4 T cells that express the VRX496 antisense env transgene
will lead to a sustained and higher level engraftment. We further hypothesize that the transgene will confer
antiviral effects. Two clinical trials are proposed to test these hypotheses. First, we will perform a multipledose
phase l/ll study in patients whose viral replication is suppressed on HAART. Structured treatment
interruption will be carried out to assess antiviral efficacy, and lymphoid biopsies will be used to determine
tissue trafficking of the engineered CD4 T cells. In trial #2 we will test a lentiviral vector developed in project
3 that expresses a more potent antiviral product. We will compare the relative survival of the T cells
transduced with the second generation vector to cells transduced with the original VRX496 vector tested in
trial #1. Together, these trials will represent the first formal efficacy tests of lentiviral engineered T cells for
their potential to serve as a potent antiviral therapy for treatment of HIV-1 infection. This project interacts
with projects 2, and 3, and the project relies on Cores A and B for cGMP lentiviral vector manufacturing and
for clinical grade T cell expansion and transduction technology
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering the Next Generation of T Cells
-
批准号:10578324
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2019
-
负责人:CARL H. JUNE
-
依托单位:
Engineering the next generation of T cells
-
批准号:10064451
-
项目类别:
-
资助金额:$23.31万
-
财政年份:2019
-
负责人:CARL H. JUNE
-
依托单位:
Directing the metabolic fate of CAR T cells
-
批准号:10364746
-
项目类别:
-
资助金额:$42.37万
-
财政年份:2018
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
-
批准号:10713199
-
项目类别:
-
资助金额:$278.23万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells
-
批准号:10245064
-
项目类别:
-
资助金额:$31.74万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Core A: Administrative and Biostatistics Core
-
批准号:10245066
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells
-
批准号:9982244
-
项目类别:
-
资助金额:$24.16万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
-
批准号:9280418
-
项目类别:
-
资助金额:$289.74万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
-
批准号:9982239
-
项目类别:
-
资助金额:$170.2万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Core A: Administrative and Biostatistics Core
-
批准号:9982247
-
项目类别:
-
资助金额:$11.2万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
-
批准号:10245062
-
项目类别:
-
资助金额:$219.44万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Core A: Administrative and Clinical Translational Core
-
批准号:10713203
-
项目类别:
-
资助金额:$24.8万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8601689
-
项目类别:
-
资助金额:$48.93万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
Role of co-receptor modified cells in HIV infection
-
批准号:8889623
-
项目类别:
-
资助金额:$156.67万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8989883
-
项目类别:
-
资助金额:$23.77万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
Role of co-receptor modified cells in HIV infection
-
批准号:8469110
-
项目类别:
-
资助金额:$128.7万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
Role of co-receptor modified cells in HIV infection
-
批准号:8519303
-
项目类别:
-
资助金额:$131.48万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8243893
-
项目类别:
-
资助金额:$51.14万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8442843
-
项目类别:
-
资助金额:$47.42万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
FACSAria II Cell Sorter for Non-Biohazardous Cells
-
批准号:7793915
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2010
-
负责人:CARL H. JUNE
-
依托单位:
海外基金